Michael S. Leapman, MD; Rong Wang, PhD; Henry Park, MD, MPH; et al.
free access
JAMA Oncol. 2022;8(1):41-47. doi:10.1001/jamaoncol.2021.5143
This cohort study uses deidentified claims data from Blue Cross Blue Shield beneficiaries aged 40 to 89 years to evaluate changes in rates of prostate-specific antigen testing after the 2017 revision of the US Preventive Services Task Force guideline on prostate cancer screening.
Christopher J. D. Wallis, MD, PhD; Zhiguo Zhao, MS; Li-Ching Huang, PhD; et al.
free access
JAMA Oncol. 2022;8(1):50-59. doi:10.1001/jamaoncol.2021.5160
This cohort study assesses whether an independent association between treatment modality and posttreatment regret mediates functional outcomes among men with localized prostate cancer.
Arla Vettenranta, MD; Teemu J. Murtola, MD, PhD; Jani Raitanen, MSc; et al.
free access
JAMA Oncol. 2022;8(1):61-68. doi:10.1001/jamaoncol.2021.5672
This post hoc subgroup analysis of a cohort from a population-based randomized clinical trial investigates the outcomes of prostate-specific antigen screening for prostate cancer among men who concomitantly use statin drugs.
Mariana Chavez-MacGregor, MD, MSC; Xiudong Lei, PhD; Hui Zhao, PhD; et al.
free access
has active quiz
JAMA Oncol. 2022;8(1):69-78. doi:10.1001/jamaoncol.2021.5148
This cohort study examines the association of cancer type, recent cancer treatment, and other factors with the outcomes of individuals with COVID-19 with or without cancer.
Matthew A. Kutny, MD; Todd A. Alonzo, PhD; Oussama Abla, MD; et al.
free access
JAMA Oncol. 2022;8(1):79-87. doi:10.1001/jamaoncol.2021.5206
This noninferiority trial examines whether all-trans retinoic acid and arsenic trioxide therapy without maintenance chemotherapy is safe and noninferior to a historically used treatment in maintaining event-free survival among pediatric patients with newly diagnosed acute promyelocytic leukemia.
Winta T. Mehtsun, MD, MPH; Nadine J. McCleary, MD, MPH; Ugwuji N. Maduekwe, MD; et al.
free access
JAMA Oncol. 2022;8(1):88-95. doi:10.1001/jamaoncol.2021.5407
This cohort study describes patterns of adjuvant chemotherapy use in patients 80 years and older following surgical resection of pancreatic ductal adenocarcinoma and to compare overall survival of patients who received AC vs those who did not.
Yong Bae Kim, MD, PhD; Hwa Kyung Byun, MD, PhD; Dae Yong Kim, MD, PhD; et al.
free access
JAMA Oncol. 2022;8(1):96-105. doi:10.1001/jamaoncol.2021.6036
This randomized clinical trial evaluates the effect of internal mammary node irradiation in regional nodal irradiation on disease-free survival among women with node-positive breast cancer in South Korea.
Maximilian J. Mair, MD; Julia M. Berger; Anna S. Berghoff, MD, PhD; et al.
free access
JAMA Oncol. 2022;8(1):106-113. doi:10.1001/jamaoncol.2021.5437
This cohort study examines the development of anti鈥揝ARS-CoV-2 antibodies in patients with hematooncological cancer after COVID-19 vaccination.
OnCovid Study Group
free access
has active quiz
JAMA Oncol. 2022;8(1):114-122. doi:10.1001/jamaoncol.2021.6199
This case series assesses whether there has been time-dependent improvement in the severity of and mortality from COVID-19 in patients with cancer.
Emmanouil Fokas, MD, DPhil; Anke Schlenska-Lange, MD; Bülent Polat, MD; et al.
free access
online only
has audio
JAMA Oncol. 2022;8(1):e215445. doi:10.1001/jamaoncol.2021.5445
This secondary analysis of a randomized clinical trial investigates the treatment sequence for total neoadjuvant therapy of chemoradiotherapy followed by consolidation chemotherapy before total mesorectal excision surgery in patients with rectal cancer.
-
Audio Author Interview:
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy for Locally Advanced Rectal Cancer